ABNB vs ABT Stock Comparison

Scores Breakdown

Metric	ABNB	ABT
📈 Growth	14/30	22/30
💰 Profitability	18/20	17/20
🏦 Financial Health	15/20	15/20
💵 Valuation	10/20	12/20
⚠️ Risk (lower is better)	6/10	4/10
Overall Score	61/100	72/100

Side-by-Side Summaries

ABNB Analysis	ABT Analysis
📈 Growth & Financial Trajectory 8 quarters show revenue starting at 2.748B (2024 Q2) and ending at 2.678B (2026 Q1), a small decline; a peak of 4.095B in 2025 Q3 underscores episodic demand strength. Net income rose from 461M in 2024 Q2 to a high of 1.374B in 2025 Q3, then declined to 160M in 2026 Q1, highlighting volatility with a mid-period peak. 💰 Margins & Cash Flow Gross margin remains elevated, with gross_profit relative to revenue above ~75-85%; for 2026 Q1, gross_profit 2.097B vs. revenue 2.678B implies ~78% margin. Operating cash flow has been positive in most quarters, notably 1.708B in 2026 Q1 and 1.356B in 2025 Q3, while investing activities are generally negative and financing moves swing cash flow. 🛡️ Balance Sheet & Liquidity Balance sheet shows resilient assets of about $26.8B with current assets around $23.6B and equity near $7.64B in 2026 Q1; debt includes $2.48B long-term, supporting liquidity. This mix supports liquidity even in travel-cycle downturns, though elevated liabilities vs. equity suggest moderate leverage. ⚠️ Key Drivers & Risks Drivers: travel demand rebound, Airbnb network effects Risks: travel volatility, regulatory/competitive pressures, valuation sensitivity to growth deceleration	📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

ABNB Analysis

ABT Analysis

📈 Growth & Financial Trajectory

8 quarters show revenue starting at 2.748B (2024 Q2) and ending at 2.678B (2026 Q1), a small decline; a peak of 4.095B in 2025 Q3 underscores episodic demand strength. Net income rose from 461M in 2024 Q2 to a high of 1.374B in 2025 Q3, then declined to 160M in 2026 Q1, highlighting volatility with a mid-period peak.

💰 Margins & Cash Flow

Gross margin remains elevated, with gross_profit relative to revenue above ~75-85%; for 2026 Q1, gross_profit 2.097B vs. revenue 2.678B implies ~78% margin. Operating cash flow has been positive in most quarters, notably 1.708B in 2026 Q1 and 1.356B in 2025 Q3, while investing activities are generally negative and financing moves swing cash flow.

🛡️ Balance Sheet & Liquidity

Balance sheet shows resilient assets of about $26.8B with current assets around $23.6B and equity near $7.64B in 2026 Q1; debt includes $2.48B long-term, supporting liquidity. This mix supports liquidity even in travel-cycle downturns, though elevated liabilities vs. equity suggest moderate leverage.

⚠️ Key Drivers & Risks

Drivers: travel demand rebound, Airbnb network effects
Risks: travel volatility, regulatory/competitive pressures, valuation sensitivity to growth deceleration

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

Similar Companies

AMZN Score: 75 BKNG Score: 52 DASH Score: 69 GOOG Score: 78 GOOGL Score: 78 KEYS Score: 75 MAR Score: 54 META Score: 79 UBER Score: 71

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"